Cart
sales@molnova.com
3-Phenylbutyric acid
CAS No. 4593-90-2
3-Phenylbutyric acid( —— )
Catalog No. M27054 CAS No. 4593-90-2
3-Phenylbutyric acid isolates Rhodococcus rhodochrous PB1 from compost soil and is metabolized by initial oxidation of the benzene ring and by initial oxidation of the side chain.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 33 | In Stock |
|
| 1G | 45 | In Stock |
|
Biological Information
-
Product Name3-Phenylbutyric acid
-
NoteResearch use only, not for human use.
-
Brief Description3-Phenylbutyric acid isolates Rhodococcus rhodochrous PB1 from compost soil and is metabolized by initial oxidation of the benzene ring and by initial oxidation of the side chain.
-
Description3-Phenylbutyric acid isolates Rhodococcus rhodochrous PB1 from compost soil and is metabolized by initial oxidation of the benzene ring and by initial oxidation of the side chain.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptorprogesterone receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number4593-90-2
-
Formula Weight164.204
-
Molecular FormulaC10H12O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (609.01 mM)
-
SMILESCC(CC(O)=O)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Griesinger G, et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS One. 2020 Nov 4;15(11):e0241044.
molnova catalog
related products
-
ML329
ML329 is a small molecule inhibitor of MITF, inhibiting TRPM-1 promoter activity.
-
Cyclo(Leu-Ala)
Cyclo(Leu-Ala) is the Diketopiperazine.
-
Examorelin
Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?
